Meta-Analysis: Immune-Related Adverse Events Are Associated With Improved Effectiveness of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
4798 patients), irAEs occurrence correlated with superior ORR (OR, 2.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Early irAEs detection and corticosteroid management preserve survival benefits. However, more large-scale prospective studies are needed to verify our findings.
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.7%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[BACKGROUND] While immune-related adverse events (irAEs) have been linked to improved outcomes in melanoma and non-small cell lung cancer (NSCLC), their prognostic role in hepatocellular carcinoma (HC
- 95% CI 1.64-2.89
- 연구 설계 meta-analysis
APA
Liu S, Li Z, et al. (2026). Meta-Analysis: Immune-Related Adverse Events Are Associated With Improved Effectiveness of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.. Alimentary pharmacology & therapeutics, 63(2), 188-202. https://doi.org/10.1111/apt.70427
MLA
Liu S, et al.. "Meta-Analysis: Immune-Related Adverse Events Are Associated With Improved Effectiveness of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.." Alimentary pharmacology & therapeutics, vol. 63, no. 2, 2026, pp. 188-202.
PMID
41116751 ↗
Abstract 한글 요약
[BACKGROUND] While immune-related adverse events (irAEs) have been linked to improved outcomes in melanoma and non-small cell lung cancer (NSCLC), their prognostic role in hepatocellular carcinoma (HCC), a malignancy arising in a unique immune microenvironment shaped by chronic inflammation and cirrhosis, remains unexplored. This meta-analysis investigated the relationship between irAEs and the effectiveness of immune checkpoint inhibitors (ICIs) in HCC.
[METHODS] Following PRISMA guidelines, we systematically reviewed studies from PubMed, Embase and the Cochrane Library (through December 2024) that evaluated the association between irAEs and ICIs' effectiveness in HCC. The primary outcomes were progression-free survival (PFS) and overall survival (OS), and the secondary outcomes were objective response rate (ORR) and disease control rate (DCR). Subgroup analyses assessed irAEs' types, severity and corticosteroid impact.
[RESULTS] Among 24 retrospective studies (4798 patients), irAEs occurrence correlated with superior ORR (OR, 2.18; 95% CI, 1.64-2.89), DCR (OR, 3.09; 95% CI, 1.81-5.27), PFS (HR, 0.62; 95% CI, 0.51-0.75) and OS (HR, 0.76; 95% CI, 0.61-0.95). Dermatologic and endocrine irAEs were associated with improved survival (PFS: HR, 0.45 and 0.50; OS: HR, 0.51 and 0.59, respectively), while pulmonary, gastrointestinal and hepatobiliary irAEs did not show such relations. Low-grade irAEs (Grades 1 and 2) were linked to better survival (PFS: HR, 0.47; OS: HR, 0.48), unlike high-grade events. Corticosteroid use for irAEs management did not impair survival (PFS: HR, 0.97; OS: HR, 0.91).
[CONCLUSION] irAEs, particularly dermatologic, endocrine and low-grade events, were associated with improved ICIs' effectiveness in HCC. Early irAEs detection and corticosteroid management preserve survival benefits. However, more large-scale prospective studies are needed to verify our findings.
[METHODS] Following PRISMA guidelines, we systematically reviewed studies from PubMed, Embase and the Cochrane Library (through December 2024) that evaluated the association between irAEs and ICIs' effectiveness in HCC. The primary outcomes were progression-free survival (PFS) and overall survival (OS), and the secondary outcomes were objective response rate (ORR) and disease control rate (DCR). Subgroup analyses assessed irAEs' types, severity and corticosteroid impact.
[RESULTS] Among 24 retrospective studies (4798 patients), irAEs occurrence correlated with superior ORR (OR, 2.18; 95% CI, 1.64-2.89), DCR (OR, 3.09; 95% CI, 1.81-5.27), PFS (HR, 0.62; 95% CI, 0.51-0.75) and OS (HR, 0.76; 95% CI, 0.61-0.95). Dermatologic and endocrine irAEs were associated with improved survival (PFS: HR, 0.45 and 0.50; OS: HR, 0.51 and 0.59, respectively), while pulmonary, gastrointestinal and hepatobiliary irAEs did not show such relations. Low-grade irAEs (Grades 1 and 2) were linked to better survival (PFS: HR, 0.47; OS: HR, 0.48), unlike high-grade events. Corticosteroid use for irAEs management did not impair survival (PFS: HR, 0.97; OS: HR, 0.91).
[CONCLUSION] irAEs, particularly dermatologic, endocrine and low-grade events, were associated with improved ICIs' effectiveness in HCC. Early irAEs detection and corticosteroid management preserve survival benefits. However, more large-scale prospective studies are needed to verify our findings.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Serum BDNF, PD-1, MMP-9 in AECOPD: prognostic value and a dual-axis risk model.
- Isolated pulmonary lymphangitic carcinomatosis as the initial manifestation of renal cell carcinoma.
- Early prediction of pathologic complete response to neoadjuvant chemotherapy based on longitudinal total choline of MR spectroscopy in patients with breast cancer.
- RNA‑binding proteins as epithelial transcriptome orchestrators in gastric cancer: Immune‑metabolic crosstalk and therapeutic vulnerability (Review).
- A case of breast acinar cell carcinoma combined with metaplastic carcinoma.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.